Dravet syndrome is an infantile-onset developmental and epileptic encephalopathy associated with drug-resistant seizures. In GWPCARE, a highly purified form of CBD was applied. The 199 children and adolescents with Dravet syndrome and drug-resistant seizures who participated, had a mean age of 9 years. They were randomised 1:1:1 to placebo or CBD in doses of 10 or 20 mg/kg/day (CBD10 or CBD20) as add-on anticonvulsant therapy.
Convulsive seizures during 14 weeks of treatment were reduced 27% in the placebo group, 49% in the CBD10 group (P=0.0095), and 46% in the CBD20 group (P=0.0299). There were also significantly more patients with a ā„50% reduction in convulsive seizures: 26% vs 44% (P=0.0332) and 49% (P=0.0069), respectively, as well as a higher reduction in total seizures: 30% vs 56% (P=0.0003) and 47% (P=0.0255). The incidence of adverse events was similar across all groups, around 89%. However, serious adverse events were reported in 15%, 20%, and 25% of patients, respectively. There were only discontinuations due to adverse events in the CBD20 group (7%). Elevated transaminases exceeding 3 times the upper limit of normal occurred in 5% of CBD10 and 19% of CBD20 patients; all elevations resolved. The authors concluded that any dose increase above 10 mg/kg/day should be guided by individual efficacy and safety.
1. Miller I, et al. AAN 2019, emerging science 006.
Posted on
Previous Article
« Encouraging results zilucoplan in myasthenia gravis Next Article
Leukaemia and hypertension therapies tested in Parkinson’s disease »
« Encouraging results zilucoplan in myasthenia gravis Next Article
Leukaemia and hypertension therapies tested in Parkinson’s disease »
Table of Contents: AAN 2019
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimer's Disease and other Dementias
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Epilepsy
Headache and Migraine
Multiple Sclerosis and NMOSD
Immune tolerance by peptide-loaded tolerogenic dendritic cells
Biotin, ocrelizumab, and ibudilast in progressive MS
No increased MS relapse risk postpartum
Neuromuscular Disorders
First-ever effective and safe treatment of CMT1A
Parkinsonās Disease and other Movement Disorders
Leukaemia and hypertension therapies tested in Parkinson’s disease
Stroke
Miscellaneous
Possibly lifesaving therapy in refractory PML
New AAN guideline for treating Tourette syndrome
Subspecialty teleneurology: feasible and highly valued
Related Articles
July 30, 2019
New AAN guideline for treating Tourette syndrome
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com